Trade Cellectar Biosciences, Inc. - CLRB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.03 |
| Open | 2.98 |
| 1-Year Change | 111.35% |
| Day's Range | 2.95 - 3.07 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 2.99 | -0.07 | -2.29% | 3.06 | 3.08 | 2.92 |
| Apr 24, 2024 | 3.03 | -0.05 | -1.62% | 3.08 | 3.15 | 2.98 |
| Apr 23, 2024 | 3.09 | -0.05 | -1.59% | 3.14 | 3.26 | 3.09 |
| Apr 22, 2024 | 3.16 | 0.14 | 4.64% | 3.02 | 3.20 | 2.94 |
| Apr 19, 2024 | 3.01 | 0.01 | 0.33% | 3.00 | 3.13 | 2.99 |
| Apr 18, 2024 | 3.02 | -0.18 | -5.63% | 3.20 | 3.20 | 2.99 |
| Apr 17, 2024 | 3.18 | -0.11 | -3.34% | 3.29 | 3.34 | 3.14 |
| Apr 16, 2024 | 3.28 | 0.01 | 0.31% | 3.27 | 3.33 | 3.21 |
| Apr 15, 2024 | 3.30 | -0.19 | -5.44% | 3.49 | 3.51 | 3.26 |
| Apr 12, 2024 | 3.48 | -0.18 | -4.92% | 3.66 | 3.69 | 3.45 |
| Apr 11, 2024 | 3.68 | 0.20 | 5.75% | 3.48 | 3.71 | 3.48 |
| Apr 10, 2024 | 3.47 | -0.17 | -4.67% | 3.64 | 3.65 | 3.43 |
| Apr 9, 2024 | 3.71 | -0.04 | -1.07% | 3.75 | 3.81 | 3.66 |
| Apr 8, 2024 | 3.78 | -0.01 | -0.26% | 3.79 | 3.80 | 3.64 |
| Apr 5, 2024 | 3.73 | 0.04 | 1.08% | 3.69 | 3.76 | 3.63 |
| Apr 4, 2024 | 3.70 | -0.29 | -7.27% | 3.99 | 4.12 | 3.69 |
| Apr 3, 2024 | 3.97 | 0.02 | 0.51% | 3.95 | 3.99 | 3.90 |
| Apr 2, 2024 | 3.97 | 0.18 | 4.75% | 3.79 | 4.02 | 3.72 |
| Apr 1, 2024 | 3.91 | -0.13 | -3.22% | 4.04 | 4.05 | 3.80 |
| Mar 28, 2024 | 3.95 | 0.11 | 2.86% | 3.84 | 4.05 | 3.77 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cellectar Biosciences, Inc. Company profile
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. Through its Phospholipid drug conjugate (PDC) deliver platform the Company is focused on to develop PDCs that are designed to target cancer cells. The Company's pipeline consists of clinical and pre-clinical product candidates. Its lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells. PDC product candidates also include CLR 1900, 2000 and 12120 series of conjugated compounds, which is being researched independently and through partnerships. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis a pathway for treating cancers. CLR 2000 Series is a collaborative PDC program with Avicenna Oncology. CLR 12120 Series is a collaborative PDC program with Orano Med for the development of PDCs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cellectar Biosciences Inc revenues was not reported. Net loss increased 60% to $24.1M. Higher net loss reflects Reaserch and development increase of 74% to $17.5M (expense), General and administrative increase of 16% to $5.5M (expense), General and administrative increase from $395K to $1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.43.
Equity composition
Common Stock $.00153 Par, 03/11, 150M auth., 731,576 issd. Insiders own 47.57%. Preferred Stock $.00001 Par, 7K auth., Ser.C 204 issd. Sr E $0.00001 Par, 408.264045 issd., 04/11, 1-for-153 reverse split. 06/14, 1-for-20 Reverse stock split. 03/16 1-for-10 Reverse stock split.
| Industry: | Pharmaceuticals (NEC) |
100 Campus Drive
FLORHAM PARK
NEW JERSEY 07932
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com